THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES

Sri International, Menlo Park CA

Investigators

Abstract

(R,R?)-4?-methoxy-1-napthylfenoterol (MNF) is a candidate anticancer agent developed within IRP, NIA that has demonstrated activity across a number of cancer cell culture lines. Preliminary studies in rodents suggest that the agent may possess anticancer action at tolerable doses and support further evaluation of the agent. There is hence a requirement for larger drug amounts to continue preclinical evaluation of MNF as well as potential clinical evaluation. To support this, Task Order 17 is to synthesize no less than 2 kg of cGMP (clinical grade) MNF material.